| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ADRA2; ADRAR; ZNF32; ADRA2R; ALPHA2AAR |
| WB Predicted band size | 49 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human ADRA2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于KEAP1抗体的3篇参考文献，包含文献名称、作者及摘要内容的简要概括：
---
1. **文献名称**: *"KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer"*
**作者**: Singh A, et al.
**摘要**: 该研究通过Western blot和免疫组化分析KEAP1蛋白在肺癌组织中的表达，使用特异性KEAP1抗体验证其与NRF2通路的调控关系，发现KEAP1缺失导致肿瘤对靶向治疗药物敏感性降低。
---
2. **文献名称**: *"Antibody-based profiling of KEAP1/NRF2 pathway components in human cancers"*
**作者**: Yamamoto M, et al.
**摘要**: 研究者开发并验证了一种高特异性KEAP1抗体，用于分析多种癌症组织中KEAP1/NRF2复合物的表达水平，揭示了KEAP1突变与抗氧化应激反应异常的相关性。
---
3. **文献名称**: *"KEAP1 mutations in NSCLC: Correlation with cytoplasmic accumulation of NRF2 and clinical outcomes"*
**作者**: Goldstein LD, et al.
**摘要**: 通过免疫荧光和共聚焦显微镜技术，利用KEAP1抗体研究非小细胞肺癌(NSCLC)中KEAP1突变对NRF2亚细胞定位的影响，发现突变导致NRF2核易位增加，与患者预后不良相关。
---
如果需要具体文献的DOI或发表年份，可进一步补充检索。
The KEAP1 (Kelch-like ECH-associated protein 1) antibody is a crucial tool for studying the KEAP1-NRF2 pathway, a central regulatory system in cellular defense against oxidative and electrophilic stress. KEAP1 acts as a substrate adaptor for a Cullin 3-based ubiquitin ligase complex, targeting the transcription factor NRF2 (Nuclear factor erythroid 2-related factor 2) for proteasomal degradation under basal conditions. During oxidative stress, KEAP1’s cysteine residues undergo modifications, disrupting its interaction with NRF2. This stabilizes NRF2. allowing its translocation to the nucleus to activate antioxidant response element (ARE)-driven genes, which encode detoxifying enzymes and cytoprotective proteins.
KEAP1 antibodies are widely used in research to detect KEAP1 protein expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. Dysregulation of the KEAP1-NRF2 axis is implicated in various diseases, including cancer, neurodegenerative disorders, and chronic inflammation. In cancer, somatic mutations or epigenetic silencing of KEAP1 can lead to constitutive NRF2 activation, promoting tumor progression and chemoresistance. Conversely, activating NRF2 through KEAP1 inhibition is explored therapeutically for diseases involving oxidative damage.
These antibodies aid in characterizing KEAP1’s role in disease mechanisms, drug discovery, and biomarker studies, making them vital for both basic research and translational applications.
×
